ATTENUATION OF HYPOCRETIN/OREXIN SIGNALING IS ASSOCIATED WITH INCREASED MORTALITY RISK AFTER MYOCARDIAL INFARCTION
Tématický okruh: Sekundární prevence | |
Typ: Ústní sdělení - lékařské , Číslo v programu: 389 | |
Etický kodex: Konzultant: ServierPřednášková činnost: Servier Podpora výzkumu / granty: Supported by Ministry of Health of the Czech Republic, grant nr. NV 19-09-00125 and by the project National Institute for Research of Metabolic and Cardiovascular Diseases (Programme EXCELES, Project No. LX22NPO5104) - Funded by the European Union - Next Generation EU. | |
Wohlfahrt P.1, Melenovský V.2, Jarolím P.3, Kotrč M.2, Jenča D.2, Dlouhá D.2, Šramko M.2, Kotrč M.2, Mrázková J.2, Piťha J.2, Adámková V.4, Kautzner J.2 1 Pracoviště preventivní kardiologie, IKEM, Praha, 2 Klinika kardiologie, IKEM, Praha, 3 Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, United States, 4 Pracoviště preventivní kardiologie, IKEM | |
Aims Hypocretin/orexin system has been shown to play a role in heart failure. Whether it also influences myocardial infarction (MI) outcomes is unknown. We evaluated the effect of rs7767652 minor allele T associated with decreased transcription of the hypocretin/orexin receptor-2 and circulating Orexin A concentrations on mortality risk after MI. | |